Boehringer, Bayer Kinase Inhibitors Offer Oral Option In HER2-Mutated Lung Cancer

Both Drugs In Phase III First-Line Trials

 
• By Mandy Jackson
  
3d Human lungs healthcare and medical abstract background
Zongertinib and BAY 2927088 are the most advanced HER2 TKIs for NSCLC • Source: Shutterstock

More from Clinical Trials

More from R&D